CLARIVATE PLC
$ 2.35
39.88%
24 Feb - close price
- Market Cap 1,129,328,000 USD
- Current Price $ 2.35
- High / Low $ 2.39 / 2.10
- Stock P/E N/A
- Book Value 7.41
- EPS -0.57
- Next Earning Report 2026-02-24
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA 0.01 %
- ROE -0.08 %
- 52 Week High 4.77
- 52 Week Low 1.66
About
Clarivate Plc, an information services and analytics company, provides analysis and structured information for the discovery, protection and commercialization of scientific research, innovations and brands. The company is headquartered in London, the United Kingdom.
Analyst Target Price
$4.48
Quarterly Earnings
| Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | Dec 2022 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2025-10-29 | 2025-07-30 | 2025-05-06 | 2025-02-25 | 2024-11-06 | 2024-08-06 | 2024-05-08 | 2024-02-27 | 2023-11-07 | 2023-08-03 | 2023-05-09 | 2023-03-01 |
| Reported EPS | 0.18 | -0.11 | 0.14 | 0.21 | 0.19 | 0.2 | 0.14 | 0.23 | 0.21 | 0.21 | 0.18 | 0.22 |
| Estimated EPS | 0.16 | 0.17 | 0.116 | 0.2024 | 0.19 | 0.18 | 0.14 | 0.21 | 0.18 | 0.2 | 0.15 | 0.17 |
| Surprise | 0.02 | -0.28 | 0.024 | 0.0076 | 0 | 0.02 | 0 | 0.02 | 0.03 | 0.01 | 0.03 | 0.05 |
| Surprise Percentage | 12.5% | -164.7059% | 20.6897% | 3.7549% | 0% | 11.1111% | 0% | 9.5238% | 16.6667% | 5% | 20% | 29.4118% |
Next Quarterly Earnings
| Dec 2025 | |
|---|---|
| Reported Date | 2026-02-24 |
| Fiscal Date Ending | 2025-12-31 |
| Estimated EPS | 0.13 |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: CLVT
2026-02-24 11:51:52
Clarivate reported improved 2025 financial results, including reduced net loss and stronger cash flow, despite lower reported sales due to divestitures. The company is transitioning to a subscription-led model, aims to divest its Life Sciences & Healthcare unit to reduce leverage and focus on core markets, and projects continued organic growth and margin expansion for 2026. An analyst currently holds a "Hold" rating on CLVT stock with a $5.00 price target.
2026-02-24 11:51:52
Clarivate plc reported a Q4 net income of $3.1 million, a significant improvement from a net loss in the prior-year quarter, despite a revenue decline. The company projects adjusted EPS growth for fiscal year 2026, with anticipated adjusted earnings between $0.70 and $0.80 per share. Clarivate also announced its intention to sell its Life Sciences & Healthcare business and is currently in discussions with interested parties.
2026-02-24 11:51:52
Clarivate (CLVT) exceeded Q4 revenue expectations, reporting $617 million, and highlighted significant progress in its Value Creation Plan, including integrating AgenticAI capabilities and improving subscription services. Despite operational advancements leading to sustained revenue growth and free cash flow conversion, the company faces financial risks such as a negative Altman Z-Score and insider selling. Valuation metrics suggest potential undervaluation, but caution is warranted due to liquidity concerns and high volatility.
2026-02-24 10:51:52
Clarivate Plc has released its 2025 10-K report, detailing a 4% decrease in revenues to $2,455.2 million due to product wind-downs, yet showing significant improvement in operating income and net income. The company is actively pursuing its Value Creation Plan, focusing on AI innovation, commercial execution, and operational efficiency, aiming for continued growth despite competitive challenges and market risks.
2026-02-24 10:51:52
Clarivate Plc (CLVT) reported Q4 adjusted earnings per share of $0.20, surpassing FactSet's estimate of $0.16. The company is a global provider of transformative intelligence, offering data, insights, and analytics across Academia & Government, Intellectual Property, and Life Sciences & Healthcare segments. Industry analysts have recent ratings and price targets for Clarivate.
2026-02-24 08:51:52
This article discusses the paths forward for Sanofi's tolebrutinib and Corcept Therapeutics' relacorilant after receiving Complete Response Letters (CRLs) from the FDA. It highlights that most drugs receiving CRLs eventually gain approval, emphasizing the importance of strategic regulatory navigation and comprehensive safety characterization. The article also posits that AI-powered solutions can help companies accelerate decision-making, ensure strategic coherence, and navigate regulatory complexities in the unpredictable life sciences landscape.
